

# Health Care Worldwide

Credit Suisse – Convertible Bond Conference  
May 20, 2014 – London



## Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.


## Agenda

- Company Overview
- Business Segments
  - Fresenius Medical Care
  - Fresenius Kabi
  - Fresenius Helios
  - Fresenius Vamed
- Fresenius 0% equity-neutral convertible bond
- Outlook
- Appendix

# Company Overview



## Fresenius Group: Strong and Balanced Health Care Portfolio



1 – Before Fenwal integration costs of €54 million

2 – Based on market cap of FSE as of May 5, 2014


3 – Based on consolidated market capitalization of FSE and FME as of May 5, 2014 and consolidated net debt as of March 31, 2014

4 – Held by Fresenius ProServe GmbH, a wholly owned subsidiary of FSE


5 – Based on market cap of FMC as of May 5, 2014

6 – Before Fenwal integration costs

## Fresenius Group: Sales Distribution by Region – 2013



# Fresenius Group: Financial Results




1 - Before special items

2 - 2013 excluding Fenwal integration costs of €54 million

3 - Incl. attributable to non-controlling interest; 2013 excluding Fenwal integration costs of €40 million

4 - 2011 sales were adjusted by -€161m according to a U.S. GAAP accounting change. This solely relates to Fresenius Medical Care North America


# Fresenius Group: Organic Growth 1999 –2013






# Fresenius Group: Sustainable Organic Sales Growth in all Business Segments


Fresenius Medical Care




Fresenius Kabi







Fresenius Helios



Fresenius Vamed



# Fresenius Group: Consistent Cash Generation and Proven Track Record of Deleveraging

**CFFO margin**

**FCF margin (before acquisitions & dividends)**

**Capex in % of sales**

**Net Debt / EBITDA**


1- Pro Forma excluding advances made for the acquisition of hospitals of Rhön-Klinikum; before Fenwal integration costs

## Fresenius Group: Ideal Strategic Posture to Benefit from Major Healthcare Trends



### Aging population and higher incidence of chronic diseases

*World population aged 60+ will more than double by 2050 to >2 bn (OECD)*



### Increasing health care spending in emerging markets

*Increasing health care coverage and per capita spending (e.g. India: \$59, China: \$278, vs. USA: \$8,608; WHO)*



### Continuing growth of generics

*Approx. \$18 bn branded IV drug sales (base: 2011) go off-patent in the U.S. by 2022*




### Rise of private providers in health care services


*Further privatization of German hospital market  
Global opportunity to provide dialysis services (e.g. China, India)*

# Fresenius Group: Long-term Shareholder Returns

**21<sup>st</sup> consecutive dividend increase  
2013: +14%**



**Fresenius outperforms index**



Source: Bloomberg; dividends reinvested

# Business Segments




## Fresenius Medical Care: Global Market Leader in Dialysis

- World leader in dialysis products and services treating 270,122 patients in 3,250 clinics worldwide<sup>1</sup>
- Provide highest standard of patient care
  - Vertical integration
  - High quality products & services
  - Complete therapy offerings
- Leader in growing market
  - Dialysis market growing 4% cc and estimated to reach around \$100 bn by 2020
  - Patient growth driven by age, life style and mortality reduction

1 – As of December 31, 2013

### Industry Dynamics

~6% global patient growth p.a.;  
~3.8 million patients by 2020 expected



## Fresenius Medical Care: Key Figures 2013

<i>\$ million</i>	<b>2013</b>	<b>2012<sup>1</sup></b>	<b>Growth</b>
<b>Sales</b>	<b>14,610</b>	<b>13,800</b>	<b>+ 6%<sup>2</sup></b>
<b>EBITDA</b>	<b>2,904</b>	<b>2,931</b>	<b>- 1%</b>
<i>EBITDA margin</i>	<i>19.9%</i>	<i>21.2%</i>	
<b>EBIT</b>	<b>2,256</b>	<b>2,329</b>	<b>- 3%</b>
<i>EBIT margin</i>	<i>15.4%</i>	<i>16.9%</i>	
<b>Net income</b>	<b>1,110</b>	<b>1,118</b>	<b>- 1%</b>

1- Before one-time items

2- 5% organic growth, 1% acquisitions

## Fresenius Medical Care: Key Figures Q1/2014

<i>\$ million</i>	Q1/2014	Q1/2013	Growth
<b>Total Sales</b>	<b>3,564</b>	<b>3,464</b>	<b>+3%<sup>1</sup></b>
<b>EBITDA</b>	<b>612</b>	<b>650</b>	<b>-6%</b>
<i>EBITDA margin</i>	<i>17.2%</i>	<i>18.8%</i>	
<b>EBIT</b>	<b>445</b>	<b>493</b>	<b>-10%</b>
<i>EBIT margin</i>	<i>12.5%</i>	<i>14.2%</i>	
<b>Net income</b>	<b>205</b>	<b>225</b>	<b>-9%</b>


1 – 3% organic growth, 1% acquisitions , -1% currency effect



# Fresenius Kabi: A Worldwide Leading Hospital Supplier


- Comprehensive product portfolio for critically and chronically ill patients
  - IV Drugs
  - Clinical Nutrition
  - Infusion Therapy
  - Medical Devices / Transfusion Technology
- Global addressable market: >€25 bn
- Leading market positions
- Focus on organic growth driven by geographic product rollout and robust product pipeline
- Aim to expand the business through selective acquisitions

## 2013 Sales by Region




# Fresenius Kabi: Profitability Improvement


**Sales in € m**



**EBITDA in € m**



**EBITDA Margin (in %)**



1 – 2013 adjusted for Fenwal integration costs

## Fresenius Kabi: Key Figures 2013

<i>€ million</i>	<b>2013<sup>1</sup></b>	<b>2012</b>	<b>Growth</b>
<b>Sales</b>	<b>4,996</b>	<b>4,539</b>	<b>+ 10%<sup>2</sup></b>
- Infusion Therapy	980	1,010	- 3 %
- I.V. Drugs	1,733	1,701	+2 %
- Clinical Nutrition	1,332	1,314	+1 %
- Medical Devices/ Transfusion Technology	951	514	+85%
<b>EBITDA<sup>1</sup></b>	<b>1,143</b>	<b>1,101</b>	<b>+ 4%</b>
<i>EBITDA margin</i>	<i>22.9%</i>	<i>24.3%</i>	
<b>EBIT<sup>1</sup></b>	<b>926</b>	<b>934</b>	<b>- 1%</b>
<i>EBIT margin</i>	<i>18.5%</i>	<i>20.6%</i>	
<b>Net income</b>	<b>487</b>	<b>444</b>	<b>+ 10%</b>

1 - Before one-time costs

2 - 5% organic growth, -4% currency effect, 9% net acquisitions

## Fresenius Kabi: Key Figures Q1/2014

<i>€ million</i>	<b>Q1/2014</b>	<b>Q1/2013</b>	<b>Growth</b>
<b>Sales</b>	<b>1,213</b>	<b>1,260</b>	<b>-4%<sup>2</sup></b>
- Infusion Therapy	230	250	-8%
- I.V. Drugs	441	460	-4%
- Clinical Nutrition	318	326	-2%
- Medical Devices/ Transfusion Technology	224	224	+0%
<b>EBITDA<sup>1</sup></b>	<b>253</b>	<b>288</b>	<b>-12%</b>
<i>EBITDA margin</i>	<i>20.9%</i>	<i>22.9%</i>	
<b>EBIT<sup>1</sup></b>	<b>201</b>	<b>237</b>	<b>-15%</b>
<i>EBIT margin</i>	<i>16.6%</i>	<i>18.8%</i>	
<b>Net income<sup>1</sup></b>	<b>106</b>	<b>119</b>	<b>-11%</b>

1 – before Fenwal integration costs

2 – 1% organic growth, -5% currency effect

# Fresenius Helios: Landmark Hospital Acquisition Provides Excellent Long-Term Growth Opportunities

- Received antitrust approval, acquisition closed on February 27, 2014
- Consolidated ~70% of the acquired business as of Jan 1; ~20% as of March 1; for one hospitals approval of municipal shareholders pending
- Focus on integration
  - 1<sup>st</sup> steps: integrate clinics into HELIOS' regional organization; e.g. combine procurement
- Synergies of ~€85 million p.a. by 2015; starting 2014
- Integration costs of ~€80 million; vast majority in 2014

1- Pro forma closing

Largest German network – 110 hospitals<sup>1</sup>  
Majority of population has access to a HELIOS hospital within one hour's drive



## Fresenius Helios: Key Figures 2013

<i>€ million</i>	<b>2013</b>	<b>2012</b>	<b>Growth</b>
<b>Sales</b>	<b>3,393</b>	<b>3,200</b>	<b>+6%<sup>1</sup></b>
<b>EBITDA</b>	<b>508</b>	<b>432</b>	<b>+18%</b>
<i>EBITDA margin</i>	<i>15.0%</i>	<i>13.5%</i>	
<b>EBIT</b>	<b>390</b>	<b>322</b>	<b>+21%</b>
<i>EBIT margin</i>	<i>11.5%</i>	<i>10.1%</i>	
<b>Net income<sup>2</sup></b>	<b>275</b>	<b>203</b>	<b>+35%</b>

1 – 3% organic growth, 3% net acquisitions

2- Bad debt level of German hospitals extremely low, e.g. 0,2% bad debt of Fresenius Helios 2013 in % of sales

## Fresenius Helios: Key Figures Q1/2014

<i>€ million</i>	<b>Q1/2014</b>	<b>Q1/2013</b>	<b>Growth</b>
<b>Sales</b>	<b>1,227</b>	<b>841</b>	<b>+46%<sup>2</sup></b>
<b>EBITDA<sup>1</sup></b>	<b>158</b>	<b>114</b>	<b>+39%</b>
<i>EBITDA margin</i>	<i>12.9%</i>	<i>13.6%</i>	
<b>EBIT<sup>1</sup></b>	<b>114</b>	<b>87</b>	<b>+31%</b>
<i>EBIT margin</i>	<i>9.3%</i>	<i>10.3%</i>	
<b>Net income</b>	<b>77</b>	<b>56</b>	<b>+38%</b>


1 – Excluding €22 million of book gain from the divestments of two Helios hospitals

2 – 4% organic growth, 44% acquisitions, -2% divestitures

# Fresenius Vamed: A Leading Global Specialist in Hospital Projects and Services

- Specialized in project development building hospital infrastructure and providing hospital services (technical services and operational management)
- Track record:
  - >600 health care projects in 70 countries successfully completed
  - Services provided to 140 hospitals and 50,000 beds globally
- Continuous demand for hospital infrastructure and operating efficiency; key markets Europe, Asia-Pacific, Africa

## 2013 Sales by Business






## Fresenius Vamed: Achievements 2013

- Outstanding year with 21% sales growth, exceeding €1 billion sales target one year ahead of plan
- Project business: 5-year sales CAGR of 12%; 2013 order entry (€744 m) at all-time high – driving further growth
- Service business: expansion with long-term contracts, creating a more balanced portfolio



Technical Service Contract – University Medical Center Hamburg-Eppendorf

### Expansion of Service Business (% of total Sales)



## Fresenius Vamed: Key Figures 2013

<i>€ million</i>	<b>2013</b>	<b>2012</b>	<b>Growth</b>
<b>Total Sales</b>	<b>1,020<sup>1</sup></b>	<b>846</b>	<b>21%<sup>1</sup></b>
<b>EBITDA</b>	<b>65</b>	<b>59</b>	<b>10%</b>
<i>EBITDA margin</i>	<i>6.4%</i>	<i>7.0%</i>	
<b>EBIT</b>	<b>55</b>	<b>51</b>	<b>8%</b>
<i>EBIT margin</i>	<i>5.4%</i>	<i>6.0%</i>	
<b>Net income</b>	<b>37</b>	<b>35</b>	<b>6%</b>
Order intake <sup>2</sup>	744	657	13%

1 – 13% organic growth, 8% acquisitions

2 – project business only

## Fresenius Vamed: Key Figures Q1/2014

<i>€ million</i>	Q1/2014	Q1/2013	Growth
<b>Total Sales</b>	<b>191</b>	<b>184</b>	<b>+4%<sup>1</sup></b>
<b>EBITDA</b>	<b>8</b>	<b>7</b>	<b>+14%</b>
<i>EBITDA margin</i>	4.2%	3.8%	
<b>EBIT</b>	<b>6</b>	<b>5</b>	<b>+20%</b>
<i>EBIT margin</i>	3.1%	2.7%	
<b>Net income</b>	<b>4</b>	<b>3</b>	<b>+33%</b>
Order intake	115	93	+24%
Order backlog	1,170	1,139 <sup>2</sup>	+3%

1 - -2% organic growth, acquisitions 6%

2 - as of December 31, 2013

## Investment Highlights

Leading market positions

Diversified revenue base with four strong business segments

Global presence in growing, non-cyclical markets

Proven ability to integrate acquisitions

Clear track record of and commitment to de-leveraging

Strong financial performance and cash flow generation



# Fresenius 0% equity-neutral convertible bonds due 2019




## Fresenius 0% equity-neutral convertible bonds: Key parameters

<b>Issuer</b>	Fresenius SE & Co. KGaA
<b>Issue amount</b>	€ 500,000,000
<b>Value date</b>	March 24, 2014
<b>Maturity</b>	Sept 24, 2019
<b>Coupon</b>	0%
<b>Issue price</b>	100%
<b>Rating</b>	BB+ / Ba1
<b>Initial conversion premium</b>	35%
<b>Initial conversion price</b>	149.3786 EUR (35% above Fresenius' share reference price <sup>1</sup> )
<b>Conversion period</b>	From March 24, 2017 until 30 days prior to maturity
<b>Conversion</b>	Cash settled <sup>2</sup>

1 - The share reference price was fixed at EUR 110.65081, determined as the arithmetic average of Fresenius' daily volume-weighted average XETRA share price over a period of ten consecutive XETRA trading days, starting on March 19, 2014

2 - Any increase of Fresenius' share price above the conversion price would be offset by a corresponding value increase of the call options; dilution of Fresenius' share capital through issuance of new shares in connection with this transaction is ruled out

# Fresenius 0% equity-neutral convertible due 2019: Trading performance



# Summary and Outlook





## Fresenius Medical Care: Financial Outlook

	<b>Reported 2013</b>	<b>Guidance 2014</b>
<b>Sales</b>	\$14,600	\$15,200
<b>EBIT</b>	\$2,256	\$2.2bn
<b>Net Income</b>	\$1,110	\$1.0- 1.05 bn

- Outlook excludes potential net cost savings from the global efficiency program for 2014
- Potential acquisitions not included
- Adequate assumptions on commercial payor mix and pricing
- Adequate assumptions on drug usage and pricing
- Investments in quality / compliance systems to continue to comply with standards

# Fresenius Kabi: Financial Outlook

## Guidance 2014 (revised)

<b>Sales</b>	Organic Growth	4% ↔ 6%
<b>EBIT</b>	Margin	16.5% ↔ 18%

Significant  
ease

U.S. I.V. drug  
market shortage  
uncertainty

Ongoing

Guidance reflects

- Uncertainty about U.S. I.V. drug market shortages
- Full-year effect from restricted use of HES blood volume substitutes
- Full-year effect from prior year price cuts in China

Guidance excludes €40 – €50 million Fenwal integration costs

## Fresenius Helios & Fresenius Vamed: Financial Outlook

### Fresenius Helios excl. acquired Rhön hospitals

### Guidance 2014

<b>Sales</b>	Organic growth	3% – 5%
<b>EBIT</b>		€390 million – €410 million

Guidance excludes integration costs for acquired hospitals from Rhön Klinikum (total ~€80 million; thereof vast majority in 2014)

### Fresenius Vamed

### Guidance 2014

<b>Sales</b>	Organic growth	5% – 10%
<b>EBIT</b>	growth	5% – 10%

## Fresenius Group: Financial Outlook

### Guidance 2014<sup>1</sup>

Revenue growth  
at constant currency

12% – 15%

Net income growth<sup>2</sup>  
at constant currency

2% – 5%

2014 guidance reflects

- U.S. Medicare dialysis reimbursement cut
- Uncertainty about U.S. I.V. drug market shortages
- Full-year effects from restricted use of HES and prior year price cuts in China

1 - Guidance includes acquired Rhön hospitals

2 - Net income attributable to shareholders of Fresenius SE & Co. KGaA before integration costs for Fenwal (€30-40 m after tax) and hospitals acquired from Rhön-Klinikum (vast majority of ~€65 m in total)

## Fresenius Group: Attractive Mid-Term Growth Prospects

New Stretch Target  
~€30 billion sales  
€1.4 to €1.5 billion net income  
by 2017



Strong and Balanced Health Care Portfolio

# Appendix



## Fresenius Group: Financial Results

	<b>Sales</b>	<b>EBIT<sup>1</sup></b>	<b>Net income<sup>2</sup></b>
Q1/14	€5,212 m	€643 m	€372 m
Growth at constant currency rates	11%	-6%	-1%
Growth at actual currency rates	7%	-8%	-2%

1- 2014 before Fenwal integration costs (€1 million) and the book gain from the divestment of two HELIOS hospitals (€22 million); 2013 before Fenwal integration costs (€7 million)

2- Net income including attributable to non-controlling interest, before Fenwal integration costs (€1 million) and the book gain from the divestment of two HELIOS hospitals (€21 million); 2013 before Fenwal integration costs (€5 million)

## Fresenius Group: Financial Results by Business Segment



Q1/14	<b>Fresenius Medical Care</b>	<b>Fresenius Kabi</b>	<b>Fresenius Helios</b>	<b>Fresenius Vamed</b>
Sales Growth	US\$3,564 m 3%	€1,213 m -4%	€1,227 m 46%	€191 m 4%
EBIT Growth	US\$445 m -10%	€201 m <sup>1</sup> -15%	€114 m <sup>2</sup> 31%	€6m 20%

1- before Fenwal integration costs

2- before €22 million of book gain from the divestment of two HELIOS hospitals



# Fresenius Group: Demonstrated Strong Sales and EBITDA Growth

**Sales in € bn**

**EBITDA in € bn<sup>1</sup>**


1 - Before special items

2 - Before Fenwal integration costs of €54 million

## Fresenius Group: Key Figures 2013

<i>€m</i>	<b>2013</b>	<b>2012</b>	<b>Change actual FX rates</b>	<b>Change constant FX rates</b>
<b>Sales</b>	<b>20,331</b>	<b>19,290</b>	<b>5%</b>	<b>8%<sup>1</sup></b>
<b>EBITDA</b>	<b>3,888<sup>2</sup></b>	<b>3,851</b>	<b>1%</b>	<b>3%</b>
<b>EBIT</b>	<b>3,045<sup>2</sup></b>	<b>3,075<sup>3</sup></b>	<b>-1%</b>	<b>1%</b>
Interest, net	- 584	- 666	12%	10%
<b>EBT</b>	<b>2,461</b>	<b>2,409<sup>3</sup></b>	<b>2%</b>	<b>5%</b>
Taxes	- 683	- 702	3%	0%
<b>Net income<sup>4</sup></b>	<b>1,778<sup>5</sup></b>	<b>1,707<sup>3</sup></b>	<b>4%</b>	<b>7%</b>
<b>Employees</b>	<b>178,337<sup>6</sup></b>	<b>169,324</b>		

1 – 4% Organic sales growth, 5% acquisitions, -1% divestitures

2 – Before Fenwal integration costs of €54 million

3 – Excl. one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG as well as other one-time costs at FMC

4 – Incl. attributable to non-controlling interest

5 – Before Fenwal integration costs of €40 million

6 – as of December 31, 2013

## Fresenius Group: Key Figures Q1/2014

<i>€ million</i>	<b>Q1/2014</b>	<b>Q1/2013</b>	<b>Change actual rates</b>	<b>Change constant rates</b>
<b>Sales</b>	<b>5,212</b>	<b>4,890</b>	<b>+7%<sup>1</sup></b>	<b>+11%</b>
<b>EBITDA</b>	<b>867<sup>2</sup></b>	<b>898<sup>2</sup></b>	<b>- 3%</b>	<b>- 1%</b>
<b>EBIT</b>	<b>643<sup>2</sup></b>	<b>696<sup>2</sup></b>	<b>- 8%</b>	<b>- 6%</b>
Interest, net	- 138	- 163 <sup>2</sup>	+15%	+13%
<b>EBT</b>	<b>505<sup>2</sup></b>	<b>533<sup>2</sup></b>	<b>- 5%</b>	<b>- 3%</b>
Taxes	- 133	-155	+14%	+10%
<b>Net income<sup>3,5</sup></b>	<b>372<sup>2,3</sup></b>	<b>378<sup>2,3</sup></b>	<b>-2%</b>	<b>-1%</b>
<b>Employees</b>	<b>201,924</b>	<b>171,764<sup>4</sup></b>		

1 - 2% organic growth, 9% acquisitions, -4 % currency effect

2 - 2014 before Fenwal integration costs (€1 million) and book gain from the divestment of two Helios hospitals (€22 million); 2013 before Fenwal integration costs (€7 million)

3 - 2014 before Fenwal integration costs (€1 million) and book gain from the divestment of two Helios hospitals (€21 million). 2013 before Fenwal integration costs (€5 million)

4 - as of December 31, 2013






5 - incl. attributable to non-controlling interest

## Fresenius Group: Cash Flow 2013

€m	2013	Margin	2012	Margin	Growth YoY
<b>Operating Cash Flow</b>	<b>2,320</b>	<b>11.4%</b>	<b>2,438</b>	<b>12.6%</b>	<b>-5%</b>
Capex (net)	-1,047	-5.1%	-952	-4.9%	-10%
<b>Free Cash Flow</b> (before acquisitions and dividends)	<b>1,273</b>	<b>6.3%</b>	<b>1,486</b>	<b>7.7%</b>	<b>-14%</b>
Acquisitions (net)	-2,556		-2,299		-11%
Dividends	-491		-446		-10%
<b>Free Cash Flow</b> (after acquisitions and dividends)	<b>-1,774</b>	<b>-8.7%</b>	<b>-1,259</b>	<b>-6.5%</b>	<b>-41%</b>

## Cash Flow Development 2013

€m

	Operating CF		Capex (net)		Free Cash Flow <sup>1</sup>	
	2013	Margin	2013	Margin	2013	Margin
 FRESENIUS KABI	488	9.8%	-311	-6.3%	177	3.5%
 FRESENIUS HELIOS	258	7.6%	-167	-4.9%	91	2.7% <sup>3</sup>
 FRESENIUS VAMED	31	3.0%	-11	-1.0%	20	2.0%
Corporate/ Other	11	n/a	-10	n/a	1	n/a
 FRESENIUS excl. FMC	<b>788</b>	<b>9.2%</b> <sup>2</sup>	<b>-499</b>	<b>-5.4%</b>	<b>289</b>	<b>3.8%</b> <sup>2</sup>
 FRESENIUS Group	<b>2,320</b>	<b>11.4%</b>	<b>-1,047</b>	<b>-5.1%</b>	<b>1,273</b>	<b>6.3%</b>

1 - Before acquisitions and dividends


2 - Incl. FMC dividend

3 - 3.7% excluding €35 million of capex commitments from acquisitions

# Financing Facilities and Debt Structure




# Fresenius Group: Current Debt and Cash Flow Structure as of March 31, 2014



1 – External debt as of March 31, 2014  
 2 – Incl. Fresenius Finance B.V. and other financing subsidiaries  
 3 – Controlling stake

4 – As held by Fresenius ProServe GmbH, a wholly owned subsidiary of Fresenius SE & Co. KGaA, which provides the guarantees  
 5 – Incl. subsidiaries

# Fresenius Group: Proven Track Record of Deleveraging



1 - Pro forma incl. Renal Care Group

2 - Pro forma incl. APP Pharmaceuticals Inc., before APP-transaction related special items

3 - Pro forma incl. Damp Group, Liberty Dialysis Holdings, Inc. and Fenwal, adjusted for €6 million one-time costs related to the 2012 offer to Rhön-Klinikum AG shareholders as well as for €86 million other one-time costs at FME


4 - Pro forma excluding advances made for the acquisition of hospitals and outpatient facilities of Rhön-Klinikum AG; before Fenwal integration costs

5 - Pro forma acquired hospitals from Rhön-Klinikum. Before integration costs for Fenwal (€1 million) and the book gain from the divestment of two HELIOS hospitals (€22 million)




# Fresenius Group: Debt Maturity Profile <sup>1</sup>

## March 31, 2014



1 - based on utilization of major financing instruments

# Fresenius Group: Rating evolution



# Health Care Worldwide

